The Report
Verified funding, headquarters, and leadership news from the world's most innovative businesses
208 reports and counting
Infinimmune Raises $75M Series A for Human-Derived Antibody Drugs
Infinimmune raised a $75 million Series A co-led by Regeneron Ventures and Playground Global to advance human-derived antibody programs in atopic dermatitis and inflammatory disease.
Diagonal Therapeutics Raises $125M Series B | Antibody Therapeutics
Biotech startup Diagonal Therapeutics secures $125 million Series B for rare genetic disease treatments.
Bambusa Therapeutics raises $90M Series A at $400M valuation
Bambusa Therapeutics raises $90M in Series A at $400M valuation. Bispecific antibodies for immunology...
Star Therapeutics raises $125M Series D
Star Therapeutics raises $125M in Series D. Developing antibody therapies for autoimmune and inflammatory diseases...
Star Therapeutics raises $125M Series B at $600M valuation
Star Therapeutics raises $125M in Series B at $600M valuation. Antibody therapies for cancer...
Bambusa Therapeutics Raises $90M in Series A
Bambusa Therapeutics, a Biotech company based in San Francisco, CA, has raised $90M in Series A at a $400M valuation led by Arch Venture Partners, Foresite Capital.
Arnatar Therapeutics raises $52M Series A
Arnatar Therapeutics raises $52M in Series A. Developing therapeutics for autoimmune and inflammatory diseases...
Denali Therapeutics raises $217M Series C at $5B valuation
Denali Therapeutics raises $217M in Series C at $5B valuation. Neurodegeneration therapeutics...
Strand Therapeutics raises $153M Series B
Strand Therapeutics raises $153M in Series B. mRNA-based therapeutics developer with novel cancer treatment platform...
Showing 9 reports • Page 1 • Category: all
Stay ahead of the market
Get weekly insights delivered to your inbox. No spam, just intelligence.